Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects

NCT02028780 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Placebo to dose
DRUG: Idarucizumab
DRUG: Placebo to Idarucizumab
DRUG: dabigatran
DRUG: Idarucizumab

Sponsor

Boehringer Ingelheim